A. Menarini S.a.s.

Menarini Ricerche S.p.a.

A. Menarini Industrie Farmaceutiche Riunite S.r.l.

Malesci Istituto Farmacobiologico S.p.a.

A. Menarini Industrie Farmaceutiche Riunite

Danilo Giannotti

Carlo Alberto Maggi

Vittorio Pestellini

Alberto Meli

Mario Ghelardoni

Alessandro Giolitti

Maria Altamura

Valentina Fedi

Federico Maria Arcamone

Alessandro Sisto

Stefano Manzini

Valerio Caciagli

Giovanna Volterra

Laura Quartara

Fabrizio Bonaccorsi

Sandro Giuliani

Enzo Perrotta

Raffaello Giorgi

Cristina Di Bugno

Franco Barsini

Franco Pasqui

Rossano Nannicini

Nicholas Harmat

Antonio Guidi

Guglielmo Grimaldi

Adriano Barzanti

Carlo Ortolani

Rossella Ciappi

This invention relates to a novel process for synthesizing the product ibodutant shown in the figure below, consisting of a small number of high-yield steps involving reagents and solvents with low environmental impact, characterized by the coupling of two portions, compounds (3) and (4), one of which (3) is synthesized by coupling of 6-methyl-2-benzo[b]thiophenecarboxylic acid (1) with 1-amino-alpha-alpha-cyclopentan carboxylic acid and subsequent cyclization with oxazolone, while the other, compound (4), is obtained from suitable highly selective functionalizations of 4-aminomethylpiperidine (2).

Process for the preparation of ibodutant (MEN15596) and related intermediates

Described herein are compounds of formula (I) useful as antagonists of tachykinins in general, and in particular of neurokinin A; and the pharmaceutical formulations comprising the compounds of formula (I) 

Linear basic compounds having NK-2 antagonist activity and formulations thereof

Basic monocyclic compounds having general formula (I) useful as NK-2 antagonists are described, processes for their preparation and pharmaceutical compositions containing them are also described.

Basic monocyclic compounds having Nk2 antagonist action, processes for their preparation, and formulations containing them

Monocyclic compounds with four bifunctional residues having NK-2 antagonist action

This invention relates to novel compounds of general formula (I): ##STR1## and to pharmaceutical compositions containing them.

Bicyclic tachykinins antagonists, preparation thereof and their use in

Novel derivatives of 11-carbonyl-6,11-dihydrodibenzo[c,f][1,2,5]thiadiazepine 5,5-dioxide of the general formula ##STR1## wherein R and R.sub.1, which can be different, represent a hydrogen atom or a (C.sub.1 -C.sub.5) alkyl or (C.sub.1 -C.sub.4)hydroxyalkyl group, or R and R.sub.1 together can form a 5-membered and/or 6-membered heterocyclic ring which may contain a further heteroatom,

Novel derivatives of 6,11-dihydro-dibenzo(C,F)(1,2,5)-thiadiazepine

Compounds corresponding to the general formula ##STR1## wherein: R and R1, that may be different, represent a hydrogen atom, a halogen, an alkyl group, an alkoxy radical in which the alkyl group contains one to four carbon atoms, a nitro group, a cyano group, an amino group, an acetamino group, a sulfamidic or N-substituted sulfamidic group; R2 represents a hydrogen atom, a halogen, an alkoxy radical, an alkyl group, a phenyl group, a phenylalkyl group, a phenylalkylene or phenylalkenyl group in which the alkylene or alkenyl radical contains two to four carbon atoms, a nitro group, a cyano group, an amino group, an acetamino group, an N-substituted suylfamidic group; and R3 represents a hydrogen atom, an alkyl group, preferably containing one to three carbon atoms or a cyano group.

(Benzofuran-2-yl)imidazoles having pharmaceutical activity, their salts

The invention comprises: a derivative of 1-alkylamine-3-[4(p-alkyloxy-benzamide)phenoxy]-2-propanol of general formula I: ##STR1## where R.sub.1 is a linear or branched alkyl chain with 1 to 8 carbon atoms included, an alkenyl chain with 2 to 8 carbon atoms included, or an arylalkyl chain with 7 to 10 carbon atoms included, and R is a linear or branched alkyl group with 1 to 8 carbon atoms included;

Derivatives of

A new compound 3(4-phenyl-1-piperazinio-1-yl)-1,2-propanediol 3(theophyllin-7-yl)-1-propanesulphonate, possesses antitussive action and is therefore usable in therapy. The compound is obtained by treating 3(theophyllin-7-yl)-1-propanesulphonic acid with 3(4-phenylpiperazin-1-yl)-1,2-propanediol in a suitable solvent.

Compound having antitussive activity

Growing community of inventors

Altopascio, Italy

Danilo Giannotti